➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Harvard Business School
Colorcon
Boehringer Ingelheim
McKesson
Mallinckrodt

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MOXIDECTIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Moxidectin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00300768 ↗ Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed World Health Organization Phase 2 2006-09-01 The primary purpose of this study is to determine the safety and tolerability of moxidectin in subjects infected with O. volvulus with special emphasis on Mazzotti reactions to determine whether it is safe enough to expose a number of subjects sufficient for obtaining statistically significant data on the safety and efficacy of moxidectin relative to ivermectin. Secondary objects are to determine the pharmacokinetics of moxidectin, to obtain initial indication of the efficacy in terms of long term effect on skin microfilaria levels and an indication of the effect on the macrofilaria that may underlie the effect on skin microfilaria levels.
NCT00736697 ↗ Study Evaluating The Effect Of High-Fat Meal On Bioavailability And Pharmacokinetics Of Single Dose Of Moxidectin Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2008-11-01 The primary objective of this study is to assess the effect of a high-fat meal (breakfast) on the concentrations of moxidectin measured in the blood after a single oral administration in healthy subjects.
NCT00751764 ↗ Study Evaluating The Excretion Of Moxidectin Into The Breast Milk Of Lactating, Non-Breastfeeding Women Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2008-11-01 The purpose of this study is to evaluate the extent of moxidectin transfer into the breast milk of lactating women and to provide the initial pharmacokinetic and safety profile of moxidectin in lactating women.
NCT00790998 ↗ Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection Completed World Health Organization Phase 3 2009-04-01 This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.
NCT00856362 ↗ Study Evaluating The Co-Administration Of Moxidectin And Midazolam In Healthy Subjects Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 1 2009-04-01 The purpose of this study is to evaluate the effect of single doses of midazolam on the plasma concentration of a single dose of moxidectin in healthy young adult subjects, and to assess the safety of co-administration of moxidectin and midazolam.
NCT01035619 ↗ Pediatric Pharmacokinetics And Safety Study Of Moxidectin Withdrawn World Health Organization Phase 2 2011-04-01 The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety. This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus) infection. O volvulus is the nematode, or roundworm, that causes Onchocerciasis, also known as river blindness. Each subject will receive a single dose of 4 mg moxidectin (orally administered) and will be followed inpatient from screening through day 13 and as outpatients through month 6. The study will take place at a single research center.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Moxidectin

Condition Name

Condition Name for Moxidectin
Intervention Trials
Onchocerciasis 7
Trichuriasis 2
Strongyloides Stercoralis Infection 2
Ascariasis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Moxidectin
Intervention Trials
Onchocerciasis 8
Trichuriasis 3
Ancylostomiasis 2
Hookworm Infections 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Moxidectin

Trials by Country

Trials by Country for Moxidectin
Location Trials
Congo, The Democratic Republic of the 3
Côte D'Ivoire 2
Ghana 2
Cambodia 2
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Moxidectin
Location Trials
Wisconsin 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Moxidectin

Clinical Trial Phase

Clinical Trial Phase for Moxidectin
Clinical Trial Phase Trials
Phase 4 1
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Moxidectin
Clinical Trial Phase Trials
Not yet recruiting 10
Completed 6
Recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Moxidectin

Sponsor Name

Sponsor Name for Moxidectin
Sponsor Trials
Jennifer Keiser 4
Medicines Development Limited 4
Wyeth is now a wholly owned subsidiary of Pfizer 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Moxidectin
Sponsor Trials
Other 24
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Colorcon
AstraZeneca
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.